DiaMedica FY2024 net loss $24.4M; cash $44.1M; preeclampsia data Q2 2025

DiaMedica Therapeutics Inc.

Net loss $24.4M ($0.60/sh) vs $19.4M; R&D $19.1M, G&A $7.6M; no revenue.
Cash $44.1M at Dec 31, 2024; runway into Q3 2026; operating cash burn $22.1M.
Preeclampsia Phase 2 topline safety/efficacy data expected Q2 2025; dosing ongoing.
ReMEDy2 AIS trial: DSMB cleared new IV dosing; interim analysis of first 200 patients expected H1 2026.
Appointed Daniel J. O'Connor (former Ambrx CEO) to board in February 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.